Psilocybin Use in the U.S. Has Doubled Since 2019: What the Numbers Really Mean

The use of psilocybin, the psychoactive compound in so-called “magic mushrooms,” has more than doubled among U.S. adults between 2019 and 2023, according to newly compiled national health data. While the absolute percentage of users remains relatively small, this rapid increase highlights shifting cultural attitudes, evolving state policies, and growing interest in psychedelics for both wellness and recreation.

Key Development: Doubling of Use Rates

A multi-dataset analysis reveals that past-year psilocybin use rose from roughly 1% of U.S. adults in 2019 to about 2.1% in 2023. This is a striking change given the compound’s federal status as a Schedule I controlled substance — officially considered to have no accepted medical use and a high potential for abuse.

The increase coincides with:

• State-level reforms in Oregon and Colorado, which have legalized psilocybin therapy in licensed facilities.
• Municipal decriminalization in cities like Seattle, Oakland, and Denver.
• A surge in media coverage of psychedelic research, particularly clinical trials suggesting benefits for depression, PTSD, and substance use disorders.

Impact & Implications

The sharp rise in psilocybin use has multiple layers of impact:

1. Public Health Concerns – Poison control centers have reported a surge in psilocybin-related calls, often linked to accidental ingestion, bad trips, or microdosing experiments gone wrong. However, hospitalizations remain rare compared to other substances.
2. Policy Pressure – With usage on the rise, policymakers are under increasing pressure to update laws. Advocates argue for regulated access to reduce risks of contaminated or mislabeled products, while opponents warn of normalization without sufficient safety research.
3. Cultural Shift – The doubling of use reflects a broader mainstreaming of psychedelics, especially among millennials and Gen Z, who often view mushrooms as less harmful than alcohol or opioids.

Market & Regional Context

The trend is not uniform across the country. States with progressive drug policy experiments, such as Oregon and Colorado, are seeing the fastest normalization, while prohibition states still report low prevalence.

Meanwhile, a parallel economy is emerging around functional mushroom supplements (which contain no psilocybin) and gray-market psilocybin edibles or capsules, often sold online with questionable safety. Researchers at Oregon State University recently found that several “magic mushroom” edibles contained no detectable psilocybin, but instead synthetic substitutes or caffeine — underscoring the risks of unregulated markets.

Looking Ahead

With psilocybin use expanding rapidly, the U.S. faces a crossroads:

• Federal Rescheduling Debate: Advocates push for reclassifying psilocybin to allow for medical access, especially as FDA-approved psychedelic therapies move closer to reality.
• Therapeutic Access Models: Colorado and Oregon’s frameworks will serve as test cases for whether regulated psilocybin services can balance safety, equity, and economic opportunity.
• Public Education: Campaigns similar to those around cannabis legalization are likely to emerge, emphasizing both potential therapeutic benefits and real risks such as impaired driving.

The doubling of psilocybin use in just four years is not just a statistic — it’s a signal that America is entering a new phase in its relationship with psychedelics.